---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-022862"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2023-06-29T23:59:59+00:00"
generated_at: "2026-06-13T14:53:10.423343+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# RenovoRx announces positive interim Phase III data: RenovoGem delays progression by 8 months in pancreatic cancer

## Summary
- Interim Phase III data show RenovoGem delays cancer progression by 8 months in locally advanced pancreatic cancer.
- RenovoRx issued press release on June 29, 2023 detailing positive interim results from ongoing trial.
- RenovoGem is delivered via RenovoRx's proprietary targeted therapy platform for difficult-to-treat cancers.

## SEC filing metadata
- accession: 0001493152-23-022862
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2023-06-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000149315223022862/0001493152-23-022862-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000149315223022862/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-022862
- JSON: https://secwatch.observer/filing/0001493152-23-022862.json
- Plain text: https://secwatch.observer/filing/0001493152-23-022862.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.